Interestingly, plasma levels of Cav-1 and identified lipid species that are part of our Cav-1 sphingolipid signature increased upon treatment with eliglustat in RM-9 tumor bearing mice (Supplementary Fig. 8a, b). The gene discussed is CAV1; the disease is neoplasm.